The Duke Comprehensive Cancer Center (DCCC) was established in 1972 and has benefited from continuous recognition and funding from the National Cancer Institute (NCI) as one of the original 8 centers supported by a Cancer Center Support Grant (CCSG). Over the past 33 years of NCI support, the DCCC has developed into one of the largest and most active cancer research enterprises in the world. As a matrix center within one the nation’s premier biomedical research institutions, the DCCC leverages Duke’s enormous basic research infrastructure with the unique focus of clinical oncology research excellence. Duke’s clinical oncology research is undertaken within one of the nation’s largest clinical oncology operations, and is further enhanced by the presence of national clinical research resources such as the data and biostatistical center of the Cancer and Leukemia Group B (CALGB) and headquarters for the American College of Surgeons Oncology Group (ACOSOG). The juxtaposition of excellence in basic and clinical research enables significant opportunities for translational and population-based research studies in patients with cancer and those at risk for cancer which are supported by center, program project, or cooperative agreement grants. To optimize discovery, development and delivery of this research to the public, the DCCC is charged and empowered to serve as the center of all activities in cancer at Duke University and Duke Medical Center.
|
